Dr. Thomas Howard Cartwright MD Medical Oncologist

Dr. Thomas Cartwright is a medical oncologist in Ocala, Florida. He is affiliated with multiple hospitals in the area, including Munroe Regional Medical Center and Ocala Regional Medical Center. He received his medical degree from Northwestern University Feinberg School of Medicine and has been in practice for 34 years. Dr. Cartwright accepts several types of health insurance, listed below. He is one of 3 doctors at Munroe Regional Medical Center and one of 3 at Ocala Regional Medical Center who specialize in Medical Oncology.

Are you Dr. Thomas Cartwright? Claim your profile to make edits or add details. Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: General Oncology

Education & Medical Training

Southern Illinois University
Residency, Internal Medicine, 1976 - 1979

Emory University
Fellowship, Hematology/Oncology, 1979 - 1981

Northwestern University Feinberg School of Medicine
Class of 1976

Certifications & Licensure

American Board of Internal Medicine
Certified 35 years in Internal Medicine

American Board of Internal Medicine
Certified 33 years in Medical Oncology

American Board of Internal Medicine
Certified 22 years in Geriatric Medicine

FL State Medical License
Active through 2014

Awards, Honors & Recognition

Meaningful Use Stage 1 Certification, Centers for Medicare & Medicaid Services

Publications & Presentations

Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Cartwright, T., Kuefler, P., Cohn, A., Hyman, W., Berger, M., Richards, D., Vukelja, S., Nugent, J. E., Ruxer, R. L., Boehm, K. A., Asmar, L.

Effects of a Brief Multimedia Psychoeducational Intervention on the Attitudes and Interest of Patients With Cancer Regarding Clinical Trial Participation: A Multicenter Randomized Controlled Trial.
Jacobsen, P. B., Wells, K. J., Meade, C. D., Quinn, G. P., Lee, J. H., Fulp, W. J., Gray, J. E., Baz, R. C., Springett, G. M., Levine, R. M., Markham, M. J., Schreiber, F. J., Cartwright, T. H., Burke, J. M., Siegel, R. D., Malafa, M. P., Sullivan, D.

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.
de Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnik S, Petrylak DP

See all 26 publications

Insurances Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • AvMed Health Open Access
  • BCBS Blue Card PPO
  • BCBS Florida BlueCare HMO
  • BCBS Florida NetworkBlue
  • BCBS Florida Preferred Patient Care PPO
  • CIGNA Open Access
  • Coventry Florida - Employer Group HMO/Open Access
  • Coventry Florida - Employer Group PPO
  • First Choice
  • First Health PPO
  • Great West PPO
  • Health Net Oregon PPO
  • Humana ChoiceCare Network PPO
  • Multiplan PHCS PPO
  • Multiplan PHCS PPO - Kaiser
  • Multiplan PPO
  • ODS Network
  • PacificSource Preferred PSN
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
Find More Doctors
Doctor Finder

Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Browse Doctors by



Search all Doctors

Profiles by Doximity

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.